MA-NITTO-DENKO
31.3.2021 13:02:14 CEST | Business Wire | Press release
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc. (Headquarters: Massachusetts, USA; referred to hereafter as “Avecia”), a subsidiary of Nitto, and other related business establishments and group companies. This investment will significantly increase the manufacturing capacity of its oligonucleotide therapeutic business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005336/en/
In addition to the already existing clinical development centered around rare diseases, development of oligonucleotide therapeutics for common diseases and intractable diseases such as cancer is progressing towards commercialization.
Since the acquisition of Avecia in 2011, Nitto has continued to invest in resources in order to provide comprehensive value in raw material manufacturing, contract manufacturing of the drug substance, final formulation, contract manufacturing of drug product and analytical services. In doing so, Nitto has contributed to the growth of the oligonucleotide therapeutic market.
At Avecia headquarters in Milford MA, Avecia is expanding process and analytical development of oligonucleotide therapeutic manufacturing based on its experience in handling more than 1,200 oligonucleotide sequences to enhance its quick and reliable manufacturing process design services. Furthermore, Avecia will establish a new building and production line for commercial manufacturing of the drug substance in order to secure sufficient supply for commercial scales. The process development building is scheduled to start operations in 2021 and the commercial manufacturing building and production line are scheduled to start operations in early 2023.
Future plans include another 25 billion Japanese yen investment to further increase the supply capacity of the polymer support used for oligonucleotide therapeutic manufacturing and expand the production line of oligonucleotide therapeutics for early clinical scales.
As a manufacturer of high-performance materials, Nitto aims to realize a better society and environment through the development of new products and new functions under its brand slogan, “Innovation for Customers”. By strengthening its capacity, Nitto can seamlessly handle manufacturing from initial stages of development to commercial scales. This will allow Nitto to support the rapidly growing oligonucleotide therapeutic market and contribute to creating a safe and healthy society.
About NITTO DENKO AVECIA INC.
Nitto Denko Avecia Inc. is a leader in oligonucleotide therapeutic manufacturing and development services with facilities located in Milford (Massachusetts) and Cincinnati (Ohio). Services for DNA and RNA-based therapeutics are provided from milligram to commercial scale. For more information, please visit www.Avecia.com .
About Oligonucleotide Therapeutics
Oligonucleotide therapeutics are comprised of nucleic acids such as DNA and RNA and are considered to be the next generation of pharmaceuticals following antibody therapeutics. Due to their direct effect on gene expression, oligonucleotide therapeutics may prove to be a revolutionary medicine that enables the treatment of illnesses that were previously difficult to treat. As a result, development towards commercialization is gaining momentum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005336/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hephaestus Exits Stealth Having Raised $17.2M to Supply Rare-Earth-Free HTS Superconductors and Build Low-Cost Fusion Power21.10.2026 16:48:00 CEST | Press release
CiRi Ventures leads latest funding round as novel HTS magnets head to manufacturing in 2027, ahead of a negative triangularity reactor targeting net energy gain by 2030 Hephaestus today emerged from stealth with solutions that address two of the largest cost drivers in fusion power: the high temperature superconducting (HTS) magnets that confine the plasma, and the edge-localized modes (ELMs – major plasma instabilities) that drive up the cost and complexity of conventional reactor designs. The company also announced the close of a new funding round led by CiRi Ventures. Hephaestus was founded in London in 2019 with a single mission – to help make fusion energy cheap enough to compete on the grid. Its AI plasma solver initially swept the full space of tokamak design parameters, unconstrained by the legacy designs and materials much of the industry is already committed to, and identified negative triangularity (NT), which inverts the D-shaped plasma used in most tokamaks, as the most li
New TOURISE and LIONS Advisory Study Reveals How Creativity Creates a Commercial Advantage for Destination Growth21.10.2026 16:27:00 CEST | Press release
50% of travelers cannot remember the last advertisement they saw for a tourism company or destination, with a further 7% unsureTourism faces an $11 billion marketing investment gap: restoring the category’s share of voice to 3% would require global travel and transport ad spend to reach $43.4 billion by 202763% of Large Language Model (LLM) visibility is driven by long-term brand equity, compared with 22% from current marketing activity and 11% from citation volume TOURISE, the world’s premier platform for shaping the future of global tourism, today released IDEAS That Travel, a new report developed in collaboration with LIONS Advisory. The study finds that while travel demand is rising, tourism brands are competing for attention in a more fragmented, socially driven and AI-mediated environment, where visibility alone is no longer enough to secure preference and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026102116
DEWA International Signs 4 MoUs With Global Partners During WETEX 202621.10.2026 16:12:00 CEST | Press release
DEWA International signed four memorandums of understanding (MoUs) with leading global entities during the Water, Energy, Technology and Environment Exhibition (WETEX 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021351329/en/ DEWA International signs 4 MoUs with global partners during WETEX 2026 (Photo: AETOSWire) HE Saeed Mohammed Al Tayer, MD&CEO of Dubai Electricity and Water Authority (DEWA) and Chairman of DEWA International, said: “We are committed to building strategic partnerships with leading international institutions that possess extensive expertise in developing and implementing energy, water and infrastructure projects, while exploring future collaboration opportunities across key sectors. Through these MoUs, we aim to exchange knowledge and expertise and leverage best practices and advanced technologies. These efforts will help accelerate the transition to clean energy, enhance the resilience and ef
Picsart Launches Marketing Studio to Help Businesses Create, Test and Run Google Ads21.10.2026 16:03:00 CEST | Press release
Key Takeaways: Picsart’s new Marketing Studio brings content creation, advertising strategy, creative testing and paid distribution into one guided space. Businesses can test concepts and videos using Zappi’s consumer insights and predictive technology, then create and launch Google Ads campaigns directly within Picsart. Built primarily for small-business owners, solopreneurs and performance marketeers, Marketing Studio connects creative work with advertising performance, helping businesses use campaign results to guide what they make next. Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today launched Marketing Studio, bringing content creation, advertising strategy, creative testing and paid distribution into one connected experience. Available now, Marketing Studio combines market insights from Zappi with a Google Ads integration that lets businesses create and launch campaigns directly with
Interactive Brokers Introduces Autonomous Trading21.10.2026 16:00:00 CEST | Press release
Eligible clients can authorize connected AI to monitor 75,000+ listed stocks, options and ETFs worldwide and submit supported trades on their behalf based on criteria they define Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced IBKR Autonomous Trading, a new capability that allows eligible clients to authorize connected AI platforms to identify trading opportunities across more than 75,000 listed stocks, options and ETFs worldwide and submit supported orders within a dedicated AI Partition. Clients can create and fund their AI Partition by transferring funds from their main IBKR account, without opening a new account or making an external deposit. The AI operates based on client-defined instructions, subject to account restrictions and safeguards designed to help manage risk. Through natural language, clients can access Interactive Brokers' extensive trading capabilities and define how they want the AI to trade on their behalf. “For decades, Interactive B
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom